Mario Tama/Getty Photographs Information
Ozempic, Novo Nordisk’s (NVO) best-selling drug, will obtain annual gross sales of $17B by 2029 as it should proceed its dominance within the diabetes market, in response to a brand new report.
Knowledge analytics and consulting firm GlobalData expects Ozempic (semaglutide) gross sales to rise 23% in 2023 in comparison with final yr to $12.5B.
In Q1 2023, Novo (NVO) reported Ozempic income of DKK 19.64B (~$2.85B).
GlobalData famous that Ozempic gross sales this yr shall be 54% increased than its closest competitor, Eli Lilly’s (NYSE:LLY) Trulicity (dulaglutide), which is forecast to have $8B in gross sales. Each are glucagon-like peptide-1 receptor agonists (GLP-1 agonists).
In Q1, Lilly (LLY) reported ~$1.98B in Trulicity income, a 14% enhance from the year-ago interval.
GlobalData mentioned that the most important marketplace for Ozempic will proceed to be the US, which accounted for 65% of general gross sales in 2022. Between 2023 and 2029, it’s anticipated to generate $71B in income. That accounts for a compound annual development charge of 9% over the interval.
Ikram Triki, a medicine intelligence analyst at GlobalData, famous that Ozempic can be more and more getting used off-label as a weight-loss agent.
Semaglutide, the lively pharmaceutical ingredient in Ozempic, is identical ingredient in Novo Nordisk’s (NVO) accredited weight-loss therapy, Wegovy, although in several dosage strengths. Wegovy recorded DKK 4.56B (~$661M) in income in Q1. Semaglutide can be out there in pill kind as Rybelsus.
“The substantial weight reduction that sufferers obtain with Ozempic and different GLP1-targeting medicine makes insulin necessities decrease for sufferers with sort 2 diabetes, incentivizing each sufferers and healthcare practitioners to contemplate this remedy,” the report famous.
Though the report would not point out it, Lilly’s Mounjaro (tirzepatide) may put some strain on the semaglutide franchise. Whereas it’s at the moment solely accredited for sort 2 diabetes, Lilly is pursuing a weight-loss indication for it, which may come as quickly as later this yr.
Mounjaro had gross sales of $568.5M in Q1.
In a examine, people on tirzepatide achieved as much as 22.5% weight reduction over 72 weeks. These within the examine have been overweight, however didn’t have diabetes. The load loss share was better than a semaglutide examine over 68 weeks.
Extra on Novo Nordisk and Ozempic
Novo Nordisk: Transferring From Energy To Energy
Novo Nordisk: Concerning FY22 And The Serendipity Of GLP-1s
Novo Nordisk Has Some Room To Run
Stopping Novo Nordisk’s Wegovy, Ozempic could result in regaining weight – report
